Sonoma Pharmaceuticals, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Sonoma Pharmaceuticals, Inc. (SNOA) on May 22, 2019, covering events occurring on May 20, 2019. The company is incorporated in Delaware and trades on The Nasdaq Stock Market LLC.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only specific financial figure disclosed relates to a transaction:
- Asset Sale Proceeds: $2.7 million purchase price for the sale of certain animal health product rights and assets.
Material Changes
On May 20, 2019, the company closed an asset purchase agreement with Petagon, Limited. Key terms include:
- Assets Sold: Certain Asian patents, trademarks, and the exclusive right to distribute animal health care products in Asia and Europe.
- Buyer: Petagon, Limited, an international importer and distributor of pet food and products.
- Continuing Relationship: Sonoma Pharmaceuticals agreed to continue supplying products to Petagon for five years at agreed-upon transfer prices.
Outlook, Risks, and Management Commentary
The filing contains forward-looking statements regarding the company's intentions and expectations. Management notes that actual outcomes may differ materially due to risks and uncertainties discussed in the Annual Report on Form 10-K. The company explicitly states it does not undertake an obligation to update forward-looking statements after the date of this report, except as required by law.
Investor Verification Checklist
- Verify the impact of the $2.7 million asset sale on the company's balance sheet and cash position in subsequent filings.
- Review the specific "agreed upon transfer prices" for the five-year supply agreement to assess future revenue stability.
- Confirm the strategic rationale for divesting Asian and European distribution rights while retaining supply obligations.
- Check for any contingent liabilities or earn-out provisions in the Asset Purchase Agreement (Exhibit 10.1) that may affect future earnings.